Artificial intelligence (AI) is closely watched by stakeholders in healthcare and life sciences. The ongoing development of AI-enabled solutions is bringing radical transformations in these sectors – impacting drug discovery, disease diagnosis, clinical trials, and precision medicine. Consequently, life science firms are increasingly investing in AI tools, as
When life sciences and AI entities foster partnerships to further innovation, they should simultaneously mitigate intellectual property (IP) risks and align interests. Legal practitioners at Finnegan suggest that it is crucial to strategically identify and address exclusive AI-related legal matters. Such issues include training data, AI models and their outputs.
While there is immense potential in the amalgamation of AI and Life Sciences, the associated IP risks can muddy collaborative ventures. Therefore, well-structured negotiations become instrumental in forming successful partnerships. Attorneys suggest AI-Life Sciences collaborations should carefully review and negotiate terms around IP generation and ownership to alleviate any potential disputes.
When negotiating these partnerships, it’s also essential for both parties to thoroughly appreciate the distinct AI-related IP challenges. The focus should be on safeguarding data essential for training AI, securing intellectual property rights on AI models, and outlining clear agreements on IP ownership of AI outputs.
Overall, while the combination of AI and life sciences presents extensive growth possibilities, it’s crucial to strategically navigate potential IP pitfalls. The key to success lies in precise identification of potential legal issues, robust mitigation strategies, and concrete agreements on IP ownership, a necessitative practice to maximize gains while minimizing risks.